{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:06:21Z","timestamp":1786982781696,"version":"build-2736575974"},"reference-count":164,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,5,5]],"date-time":"2015-05-05T00:00:00Z","timestamp":1430784000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s40266-015-0266-9","type":"journal-article","created":{"date-parts":[[2015,5,4]],"date-time":"2015-05-04T08:31:05Z","timestamp":1430728265000},"page":"453-467","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":141,"title":["A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence"],"prefix":"10.1007","volume":"32","author":[{"given":"Jacob S.","family":"Buckley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley R.","family":"Salpeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,5,5]]},"reference":[{"issue":"5","key":"266_CR1","doi-asserted-by":"crossref","first-page":"370","DOI":"10.7326\/0003-4819-148-5-200803040-00008","volume":"148","author":"A Qaseem","year":"2008","unstructured":"Qaseem A, Snow V, Cross JT Jr, et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2008;148(5):370\u20138.","journal-title":"Ann Intern Med"},{"issue":"3","key":"266_CR2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1017\/S1461145704004444","volume":"7","author":"JG Evans","year":"2004","unstructured":"Evans JG, Wilcock G, Birks J. Evidence-based pharmacotherapy of Alzheimer\u2019s disease. Int J Neuropsychopharmacol. 2004;7(3):351\u201369.","journal-title":"Int J Neuropsychopharmacol"},{"key":"266_CR3","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV-TR. 4th ed. Washington, DC; 2000."},{"issue":"1","key":"266_CR4","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jalz.2012.11.007","volume":"9","author":"M Prince","year":"2013","unstructured":"Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013;9(1):63\u201375.e2.","journal-title":"Alzheimers Dement"},{"issue":"3 Pt 1","key":"266_CR5","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1212\/WNL.43.3_Part_1.515","volume":"43","author":"DL Bachman","year":"1993","unstructured":"Bachman DL, Wolf PA, Linn RT, et al. Incidence of dementia and probable Alzheimer\u2019s disease in a general population: the Framingham Study. Neurology. 1993;43(3 Pt 1):515\u20139.","journal-title":"Neurology"},{"issue":"1","key":"266_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2012.11.006","volume":"9","author":"A Wimo","year":"2013","unstructured":"Wimo A, Jonsson L, Bond J, Prince M, Winblad B, Alzheimer Disease I. The worldwide economic impact of dementia 2010. Alzheimers Dement. 2013;9(1):1\u201311.e3.","journal-title":"Alzheimers Dement"},{"key":"266_CR7","first-page":"CD009132","volume":"9","author":"TC Russ","year":"2012","unstructured":"Russ TC, Morling JR. Cholinesterase inhibitors for mild cognitive impairment. Cochrane Database Syst Rev. 2012;9:CD009132.","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"266_CR8","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1177\/0269881110387547","volume":"25","author":"JT O\u2019Brien","year":"2011","unstructured":"O\u2019Brien JT, Burns A, BAP Dementia Consensus Group. Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol. 2011;25(8):997\u20131019.","journal-title":"J Psychopharmacol"},{"issue":"4","key":"266_CR9","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2006.07.001","volume":"2","author":"JL Cummings","year":"2006","unstructured":"Cummings JL. Challenges to demonstrating disease-modifying effects in Alzheimer\u2019s disease clinical trials. Alzheimers Dement. 2006;2(4):263\u201371.","journal-title":"Alzheimers Dement"},{"key":"266_CR10","unstructured":"Drugs for cognitive loss and dementia. Treat Guidel Med Lett. 2013;11(134):95\u2013100."},{"key":"266_CR11","first-page":"1","volume":"97","author":"PS Santaguida","year":"2004","unstructured":"Santaguida PS, Raina P, Booker L, et al. Pharmacological treatment of dementia. Evid Rep Technol Assess (Summ). 2004;97:1\u201316.","journal-title":"Evid Rep Technol Assess (Summ)"},{"key":"266_CR12","doi-asserted-by":"crossref","unstructured":"Birks J. Cholinesterase inhibitors for Alzheimer\u2019s disease. Cochrane Database Syst Rev. 2006;(1):CD005593.","DOI":"10.1002\/14651858.CD005593"},{"issue":"2 Dementia","key":"266_CR13","first-page":"457","volume":"19","author":"SS Bullain","year":"2013","unstructured":"Bullain SS, Corrada MM. Dementia in the oldest old. Continuum (Minneap Minn). 2013;19(2 Dementia):457\u201369.","journal-title":"Continuum (Minneap Minn)"},{"issue":"2","key":"266_CR14","first-page":"e274","volume":"11","author":"SS Gill","year":"2004","unstructured":"Gill SS, Bronskill SE, Mamdani M, et al. Representation of patients with dementia in clinical trials of donepezil. Can J Clin Pharmacol. 2004;11(2):e274\u201385.","journal-title":"Can J Clin Pharmacol"},{"issue":"8","key":"266_CR15","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/j.1532-5415.1997.tb02960.x","volume":"45","author":"LS Schneider","year":"1997","unstructured":"Schneider LS, Olin JT, Lyness SA, Chui HC. Eligibility of Alzheimer\u2019s disease clinic patients for clinical trials. J Am Geriatr Soc. 1997;45(8):923\u20138.","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"266_CR16","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1007\/s12603-014-0031-5","volume":"18","author":"Y Asahina","year":"2014","unstructured":"Asahina Y, Sugano H, Sugiyama E, Uyama Y. Representation of older patients in clinical trials for drug approval in Japan. J Nutr Health Aging. 2014;18(5):520\u20133.","journal-title":"J Nutr Health Aging"},{"issue":"4","key":"266_CR17","doi-asserted-by":"crossref","first-page":"e004083","DOI":"10.1136\/bmjopen-2013-004083","volume":"4","author":"LO Killin","year":"2014","unstructured":"Killin LO, Russ TC, Starr JM, Abrahams S, Della Sala S. The effect of funding sources on donepezil randomised controlled trial outcome: a meta-analysis. BMJ Open. 2014;4(4):e004083.","journal-title":"BMJ Open"},{"issue":"8","key":"266_CR18","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1111\/j.1532-5415.2008.01844.x","volume":"56","author":"JR Gilstad","year":"2008","unstructured":"Gilstad JR, Finucane TE. Results, rhetoric, and randomized trials: the case of donepezil. J Am Geriatr Soc. 2008;56(8):1556\u201362.","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"266_CR19","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000054761","volume":"20","author":"K Rockwood","year":"2001","unstructured":"Rockwood K, MacKnight C. Assessing the clinical importance of statistically significant improvement in anti-dementia drug trials. Neuroepidemiology. 2001;20(2):51\u20136.","journal-title":"Neuroepidemiology"},{"issue":"6","key":"266_CR20","first-page":"557","volume":"169","author":"KL Lanctot","year":"2003","unstructured":"Lanctot KL, Herrmann N, Yau KK, et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer\u2019s disease: a meta-analysis. CMAJ. 2003;169(6):557\u201364.","journal-title":"CMAJ"},{"issue":"2","key":"266_CR21","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/archneur.57.2.191","volume":"57","author":"HC Chui","year":"2000","unstructured":"Chui HC, Mack W, Jackson JE, et al. Clinical criteria for the diagnosis of vascular dementia: a multicenter study of comparability and interrater reliability. Arch Neurol. 2000;57(2):191\u20136.","journal-title":"Arch Neurol"},{"issue":"2","key":"266_CR22","doi-asserted-by":"crossref","first-page":"111","DOI":"10.31887\/DCNS.2009.11.2\/cqiu","volume":"11","author":"C Qiu","year":"2009","unstructured":"Qiu C, Kivipelto M, von Strauss E. Epidemiology of Alzheimer\u2019s disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci. 2009;11(2):111\u201328.","journal-title":"Dialogues Clin Neurosci"},{"issue":"5","key":"266_CR23","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1159\/000109800","volume":"14","author":"R Hebert","year":"1995","unstructured":"Hebert R, Brayne C. Epidemiology of vascular dementia. Neuroepidemiology. 1995;14(5):240\u201357.","journal-title":"Neuroepidemiology"},{"issue":"Suppl 3","key":"266_CR24","first-page":"S9","volume":"13","author":"WA Rocca","year":"1999","unstructured":"Rocca WA, Kokmen E. Frequency and distribution of vascular dementia. Alzheimer Dis Assoc Disord. 1999;13(Suppl 3):S9\u201314.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"4","key":"266_CR25","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1001\/archneur.60.4.569","volume":"60","author":"DS Knopman","year":"2003","unstructured":"Knopman DS, Parisi JE, Boeve BF, et al. Vascular dementia in a population-based autopsy study. Arch Neurol. 2003;60(4):569\u201375.","journal-title":"Arch Neurol"},{"issue":"3","key":"266_CR26","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1056\/NEJM199301213280301","volume":"328","author":"I Skoog","year":"1993","unstructured":"Skoog I, Nilsson L, Palmertz B, Andreasson LA, Svanborg A. A population-based study of dementia in 85-year-olds. N Engl J Med. 1993;328(3):153\u20138.","journal-title":"N Engl J Med"},{"issue":"11 Suppl 5","key":"266_CR27","first-page":"S4","volume":"54","author":"A Lobo","year":"2000","unstructured":"Lobo A, Launer LJ, Fratiglioni L, et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 2000;54(11 Suppl 5):S4\u20139.","journal-title":"Neurology"},{"issue":"2","key":"266_CR28","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1532-5415.2004.52058.x","volume":"52","author":"AL Fitzpatrick","year":"2004","unstructured":"Fitzpatrick AL, Kuller LH, Ives DG, et al. Incidence and prevalence of dementia in the Cardiovascular Health Study. J Am Geriatr Soc. 2004;52(2):195\u2013204.","journal-title":"J Am Geriatr Soc"},{"issue":"24","key":"266_CR29","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1212\/01.wnl.0000271090.28148.24","volume":"69","author":"JA Schneider","year":"2007","unstructured":"Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69(24):2197\u2013204.","journal-title":"Neurology"},{"issue":"2","key":"266_CR30","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1136\/jnnp-2014-307659","volume":"86","author":"HF Wang","year":"2015","unstructured":"Wang HF, Yu JT, Tang SW, et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson\u2019s disease, Parkinson\u2019s disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry. 2015;86(2):135\u201343. doi: 10.1136\/jnnp-2014-307659 .","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"266_CR31","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/mds.20527","volume":"20","author":"D Aarsland","year":"2005","unstructured":"Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson\u2019s disease. Mov Disord. 2005;20(10):1255\u201363.","journal-title":"Mov Disord"},{"issue":"3","key":"266_CR32","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1001\/archneur.1988.00520270034017","volume":"45","author":"R Mayeux","year":"1988","unstructured":"Mayeux R, Stern Y, Rosenstein R, et al. An estimate of the prevalence of dementia in idiopathic Parkinson\u2019s disease. Arch Neurol. 1988;45(3):260\u20132.","journal-title":"Arch Neurol"},{"key":"266_CR33","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/gps.930091107","volume":"9","author":"S Shergil","year":"1994","unstructured":"Shergil S, Mullan E, D\u2019ath P, Katona C. What is the clinical prevalence of Lewy body dementia? Int J Geriatr Psychiatry. 1994;9:907\u201312.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"4","key":"266_CR34","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1017\/S0033291713000494","volume":"44","author":"SA Vann Jones","year":"2014","unstructured":"Vann Jones SA, O\u2019Brien JT. The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Psychol Med. 2014;44(4):673\u201383.","journal-title":"Psychol Med"},{"issue":"10","key":"266_CR35","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1503\/cmaj.070797","volume":"178","author":"H Chertkow","year":"2008","unstructured":"Chertkow H, Massoud F, Nasreddine Z, et al. Diagnosis and treatment of dementia: 3. Mild cognitive impairment and cognitive impairment without dementia. CMAJ. 2008;178(10):1273\u201385.","journal-title":"CMAJ"},{"issue":"6","key":"266_CR36","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1177\/1756285612455733","volume":"5","author":"B Sheehan","year":"2012","unstructured":"Sheehan B. Assessment scales in dementia. Ther Adv Neurol Disord. 2012;5(6):349\u201358.","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"266_CR37","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. \u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189\u201398.","journal-title":"J Psychiatr Res"},{"key":"266_CR38","unstructured":"Crutch S. The mini mental state examination (MMSE). Fact sheet. 2013. http:\/\/www.alzheimers.org.uk\/site\/scripts\/download_info.php?downloadID=1116 . Accessed 12 Apr 2015."},{"issue":"1","key":"266_CR39","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1037\/1040-3590.8.1.48","volume":"8","author":"TN Tombaugh","year":"1996","unstructured":"Tombaugh TN, Hubley AM, McDowell I, Kristjansson B. Mini-mental state examination (MMSE) and the modified MMSE (3MS): a psychometric comparison and normative data. Psychol Assess. 1996;8(1):48\u201359.","journal-title":"Psychol Assess"},{"issue":"2","key":"266_CR40","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1532-5415.2007.01049.x","volume":"55","author":"K Kahle-Wrobleski","year":"2007","unstructured":"Kahle-Wrobleski K, Corrada MM, Li B, Kawas CH. Sensitivity and specificity of the mini-mental state examination for identifying dementia in the oldest-old: the 90+ study. J Am Geriatr Soc. 2007;55(2):284\u20139.","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"266_CR41","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0004-9514(05)70034-9","volume":"51","author":"M Galea","year":"2005","unstructured":"Galea M, Woodward M. Mini-mental state examination (MMSE). Aust J Physiother. 2005;51(3):198.","journal-title":"Aust J Physiother"},{"issue":"4","key":"266_CR42","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1590\/S0034-89102006000500023","volume":"40","author":"RA Lourenco","year":"2006","unstructured":"Lourenco RA, Veras RP. Mini-mental state examination: psychometric characteristics in elderly outpatients. Rev Saude Publica. 2006;40(4):712\u20139.","journal-title":"Rev Saude Publica"},{"issue":"11","key":"266_CR43","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","volume":"141","author":"WG Rosen","year":"1984","unstructured":"Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer\u2019s disease. Am J Psychiatry. 1984;141(11):1356\u201364.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"266_CR44","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/00002093-200110000-00003","volume":"15","author":"PM Doraiswamy","year":"2001","unstructured":"Doraiswamy PM, Kaiser L, Bieber F, Garman RL. The Alzheimer\u2019s Disease Assessment Scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer\u2019s disease. Alzheimer Dis Assoc Disord. 2001;15(4):174\u201383.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"4","key":"266_CR45","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s11682-012-9166-3","volume":"6","author":"J Skinner","year":"2012","unstructured":"Skinner J, Carvalho JO, Potter GG, et al. The Alzheimer\u2019s disease assessment scale-cognitive-plus (ADAS-Cog-Plus): an expansion of the ADAS-Cog to improve responsiveness in MCI. Brain Imaging Behav. 2012;6(4):489\u2013501.","journal-title":"Brain Imaging Behav"},{"issue":"9","key":"266_CR46","doi-asserted-by":"crossref","first-page":"952","DOI":"10.2174\/15672050113106660160","volume":"10","author":"A Khan","year":"2013","unstructured":"Khan A, Yavorsky C, DiClemente G, et al. Reliability of the Alzheimer\u2019s disease assessment scale (ADAS-Cog) in longitudinal studies. Curr Alzheimer Res. 2013;10(9):952\u201363.","journal-title":"Curr Alzheimer Res"},{"issue":"2","key":"266_CR47","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1017\/S1041610297004298","volume":"9","author":"G Weyer","year":"1997","unstructured":"Weyer G, Erzigkeit H, Kanowski S, Ihl R, Hadler D. Alzheimer\u2019s Disease Assessment Scale: reliability and validity in a multicenter clinical trial. Int Psychogeriatr. 1997;9(2):123\u201338.","journal-title":"Int Psychogeriatr"},{"issue":"Suppl 2","key":"266_CR48","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/00002093-199700112-00003","volume":"11","author":"RC Mohs","year":"1997","unstructured":"Mohs RC, Knopman D, Petersen RC, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer\u2019s Disease Assessment Scale that broaden its scope. The Alzheimer\u2019s Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(Suppl 2):S13\u201321.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"1","key":"266_CR49","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/archneur.1994.00540130067012","volume":"51","author":"M Panisset","year":"1994","unstructured":"Panisset M, Roudier M, Saxton J, Boller F. Severe impairment battery. A neuropsychological test for severely demented patients. Arch Neurol. 1994;51(1):41\u20135.","journal-title":"Arch Neurol"},{"issue":"3","key":"266_CR50","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/geront\/9.3_Part_1.179","volume":"9","author":"MP Lawton","year":"1969","unstructured":"Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9(3):179\u201386.","journal-title":"Gerontologist"},{"issue":"4","key":"266_CR51","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/alzrt48","volume":"2","author":"P Robert","year":"2010","unstructured":"Robert P, Ferris S, Gauthier S, Ihl R, Winblad B, Tennigkeit F. Review of Alzheimer\u2019s disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice? Alzheimers Res Ther. 2010;2(4):24.","journal-title":"Alzheimers Res Ther"},{"issue":"12","key":"266_CR52","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","volume":"44","author":"JL Cummings","year":"1994","unstructured":"Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308\u201314.","journal-title":"Neurology"},{"issue":"3","key":"266_CR53","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1017\/S1041610207005261","volume":"19","author":"B Reisberg","year":"2007","unstructured":"Reisberg B. Global measures: utility in defining and measuring treatment response in dementia. Int Psychogeriatr. 2007;19(3):421\u201356.","journal-title":"Int Psychogeriatr"},{"issue":"6","key":"266_CR54","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1532-5415.2011.03450.x","volume":"59","author":"DH Kim","year":"2011","unstructured":"Kim DH, Brown RT, Ding EL, Kiel DP, Berry SD. Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials. J Am Geriatr Soc. 2011;59(6):1019\u201331.","journal-title":"J Am Geriatr Soc"},{"issue":"8","key":"266_CR55","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1001\/archneur.60.8.1119","volume":"60","author":"LE Hebert","year":"2003","unstructured":"Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003;60(8):1119\u201322.","journal-title":"Arch Neurol"},{"key":"266_CR56","unstructured":"National Institute for Health and Care Excellence. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer\u2019s disease. NICE technology appraisal guidance 217. NICE; London; 2011."},{"issue":"2","key":"266_CR57","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1017\/S0033291700046730","volume":"12","author":"JC Anthony","year":"1982","unstructured":"Anthony JC, LeResche L, Niaz U, von Korff MR, Folstein MF. Limits of the \u2018Mini-Mental State\u2019 as a screening test for dementia and delirium among hospital patients. Psychol Med. 1982;12(2):397\u2013408.","journal-title":"Psychol Med"},{"issue":"7","key":"266_CR58","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1001\/archneur.65.7.963","volume":"65","author":"SE O\u2019Bryant","year":"2008","unstructured":"O\u2019Bryant SE, Humphreys JD, Smith GE, et al. Detecting dementia with the mini-mental state examination in highly educated individuals. Arch Neurol. 2008;65(7):963\u20137.","journal-title":"Arch Neurol"},{"issue":"3","key":"266_CR59","doi-asserted-by":"crossref","first-page":"158","DOI":"10.4088\/PCC.v08n0306","volume":"8","author":"FA Schmitt","year":"2006","unstructured":"Schmitt FA, Wichems CH. A systematic review of assessment and treatment of moderate to severe Alzheimer\u2019s disease. Prim Care Companion J Clin Psychiatry. 2006;8(3):158\u20139.","journal-title":"Prim Care Companion J Clin Psychiatry"},{"issue":"2","key":"266_CR60","doi-asserted-by":"crossref","first-page":"62","DOI":"10.4088\/PCC.v07n0204","volume":"7","author":"AD Benson","year":"2005","unstructured":"Benson AD, Slavin MJ, Tran TT, Petrella JR, Doraiswamy PM. Screening for early Alzheimer\u2019s disease: is there still a role for the mini-mental state examination? Prim Care Companion J Clin Psychiatry. 2005;7(2):62\u20139.","journal-title":"Prim Care Companion J Clin Psychiatry"},{"issue":"3","key":"266_CR61","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2796.2004.01388.x","volume":"256","author":"RC Petersen","year":"2004","unstructured":"Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256(3):183\u201394.","journal-title":"J Intern Med"},{"key":"266_CR62","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1471-2377-11-78","volume":"11","author":"A Pozueta","year":"2011","unstructured":"Pozueta A, Rodriguez-Rodriguez E, Vazquez-Higuera JL, et al. Detection of early Alzheimer\u2019s disease in MCI patients by the combination of MMSE and an episodic memory test. BMC Neurol. 2011;11:78.","journal-title":"BMC Neurol"},{"issue":"2","key":"266_CR63","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2165\/0002512-200926020-00005","volume":"26","author":"T Voisin","year":"2009","unstructured":"Voisin T, Vellas B. Diagnosis and treatment of patients with severe Alzheimer\u2019s disease. Drugs Aging. 2009;26(2):135\u201344.","journal-title":"Drugs Aging"},{"key":"266_CR64","doi-asserted-by":"crossref","unstructured":"Reisberg B, Jamil IA, Khan S, et al. Staging dementia. In: Abou-Saleh MT, Katona CLE, Kumar A, editors. Principles and practice of geriatric psychiatry. 3rd ed. Chichester, Hoboken: Wiley; 2011. p. 162\u2013169.","DOI":"10.1002\/9780470669600.ch31"},{"issue":"7\u20138","key":"266_CR65","first-page":"1003","volume":"109","author":"L Frolich","year":"2002","unstructured":"Frolich L. The cholinergic pathology in Alzheimer\u2019s disease: discrepancies between clinical experience and pathophysiological findings. J Neural Transm. 2002;109(7\u20138):1003\u201313.","journal-title":"J Neural Transm"},{"issue":"Suppl 17","key":"266_CR66","doi-asserted-by":"crossref","first-page":"S351","DOI":"10.1002\/mds.21683","volume":"22","author":"PT Francis","year":"2007","unstructured":"Francis PT, Perry EK. Cholinergic and other neurotransmitter mechanisms in Parkinson\u2019s disease, Parkinson\u2019s disease dementia, and dementia with Lewy bodies. Mov Disord. 2007;22(Suppl 17):S351\u20137.","journal-title":"Mov Disord"},{"key":"266_CR67","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0022-510X(02)00274-5","volume":"203\u2013204","author":"C Grantham","year":"2002","unstructured":"Grantham C, Geerts H. The rationale behind cholinergic drug treatment for dementia related to cerebrovascular disease. J Neurol Sci. 2002;203\u2013204:131\u20136.","journal-title":"J Neurol Sci"},{"issue":"2","key":"266_CR68","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/153331750502000206","volume":"20","author":"JL Molinuevo","year":"2005","unstructured":"Molinuevo JL, Llado A, Rami L. Memantine: targeting glutamate excitotoxicity in Alzheimer\u2019s disease and other dementias. Am J Alzheimers Dis Other Demen. 2005;20(2):77\u201385.","journal-title":"Am J Alzheimers Dis Other Demen"},{"issue":"Pt 4","key":"266_CR69","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/brain\/awr028","volume":"134","author":"I Ahmed","year":"2011","unstructured":"Ahmed I, Bose SK, Pavese N, et al. Glutamate NMDA receptor dysregulation in Parkinson\u2019s disease with dyskinesias. Brain. 2011;134(Pt 4):979\u201386.","journal-title":"Brain"},{"issue":"4","key":"266_CR70","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3233\/JAD-2005-7403","volume":"7","author":"MN Sabbagh","year":"2005","unstructured":"Sabbagh MN, Hake AM, Ahmed S, Farlow MR. The use of memantine in dementia with Lewy bodies. J Alzheimers Dis. 2005;7(4):285\u20139.","journal-title":"J Alzheimers Dis"},{"issue":"Suppl 3","key":"266_CR71","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1097\/00002093-199912001-00024","volume":"13","author":"HJ Mobius","year":"1999","unstructured":"Mobius HJ. Pharmacologic rationale for memantine in chronic cerebral hypoperfusion, especially vascular dementia. Alzheimer Dis Assoc Disord. 1999;13(Suppl 3):S172\u20138.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"9533","key":"266_CR72","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","volume":"368","author":"K Blennow","year":"2006","unstructured":"Blennow K, de Leon MJ, Zetterberg H. Alzheimer\u2019s disease. Lancet. 2006;368(9533):387\u2013403.","journal-title":"Lancet"},{"issue":"2","key":"266_CR73","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.bbr.2010.05.033","volume":"221","author":"C Nyakas","year":"2011","unstructured":"Nyakas C, Granic I, Halmy LG, Banerjee P, Luiten PG. The basal forebrain cholinergic system in aging and dementia. Rescuing cholinergic neurons from neurotoxic amyloid-beta42 with memantine. Behav Brain Res. 2011;221(2):594\u2013603.","journal-title":"Behav Brain Res"},{"issue":"2","key":"266_CR74","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1476-5381.2012.02057.x","volume":"167","author":"W Danysz","year":"2012","unstructured":"Danysz W, Parsons CG. Alzheimer\u2019s disease, beta-amyloid, glutamate, NMDA receptors and memantine\u2013searching for the connections. Br J Pharmacol. 2012;167(2):324\u201352.","journal-title":"Br J Pharmacol"},{"key":"266_CR75","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1742-4933-6-13","volume":"6","author":"F Iemolo","year":"2009","unstructured":"Iemolo F, Duro G, Rizzo C, Castiglia L, Hachinski V, Caruso C. Pathophysiology of vascular dementia. Immun Ageing. 2009;6:13.","journal-title":"Immun Ageing"},{"issue":"2","key":"266_CR76","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/0006-8993(94)01436-L","volume":"673","author":"JW Ni","year":"1995","unstructured":"Ni JW, Matsumoto K, Li HB, Murakami Y, Watanabe H. Neuronal damage and decrease of central acetylcholine level following permanent occlusion of bilateral common carotid arteries in rat. Brain Res. 1995;673(2):290\u20136.","journal-title":"Brain Res"},{"issue":"Suppl 3","key":"266_CR77","doi-asserted-by":"crossref","first-page":"S221","DOI":"10.1016\/S1353-8020(08)70005-1","volume":"13","author":"Y Tsuboi","year":"2007","unstructured":"Tsuboi Y, Uchikado H, Dickson DW. Neuropathology of Parkinson\u2019s disease dementia and dementia with Lewy bodies with reference to striatal pathology. Parkinsonism Relat Disord. 2007;13(Suppl 3):S221\u20134.","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"266_CR78","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.bbr.2009.12.048","volume":"221","author":"NI Bohnen","year":"2011","unstructured":"Bohnen NI, Albin RL. The cholinergic system and Parkinson disease. Behav Brain Res. 2011;221(2):564\u201373.","journal-title":"Behav Brain Res"},{"issue":"10","key":"266_CR79","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1007\/s00415-014-7439-z","volume":"261","author":"MJ Grothe","year":"2014","unstructured":"Grothe MJ, Schuster C, Bauer F, Heinsen H, Prudlo J, Teipel SJ. Atrophy of the cholinergic basal forebrain in dementia with Lewy bodies and Alzheimer\u2019s disease dementia. J Neurol. 2014;261(10):1939\u201348.","journal-title":"J Neurol"},{"issue":"4","key":"266_CR80","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1750-3639.2004.tb00082.x","volume":"14","author":"E Dalfo","year":"2004","unstructured":"Dalfo E, Albasanz JL, Martin M, Ferrer I. Abnormal metabotropic glutamate receptor expression and signaling in the cerebral cortex in diffuse Lewy body disease is associated with irregular alpha-synuclein\/phospholipase C (PLCbeta1) interactions. Brain Pathol. 2004;14(4):388\u201398.","journal-title":"Brain Pathol"},{"issue":"4","key":"266_CR81","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/syn.890190405","volume":"19","author":"MS Starr","year":"1995","unstructured":"Starr MS. Glutamate\/dopamine D1\/D2 balance in the basal ganglia and its relevance to Parkinson\u2019s disease. Synapse. 1995;19(4):264\u201393.","journal-title":"Synapse"},{"issue":"23","key":"266_CR82","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa050151","volume":"352","author":"RC Petersen","year":"2005","unstructured":"Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352(23):2379\u201388.","journal-title":"N Engl J Med"},{"issue":"24","key":"266_CR83","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1212\/WNL.0b013e3181aa52d3","volume":"72","author":"PH Lu","year":"2009","unstructured":"Lu PH, Edland SD, Teng E, et al. Donepezil delays progression to AD in MCI subjects with depressive symptoms. Neurology. 2009;72(24):2115\u201321.","journal-title":"Neurology"},{"issue":"22","key":"266_CR84","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1212\/01.wnl.0000303815.69777.26","volume":"70","author":"B Winblad","year":"2008","unstructured":"Winblad B, Gauthier S, Scinto L, et al. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology. 2008;70(22):2024\u201335.","journal-title":"Neurology"},{"issue":"16","key":"266_CR85","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1503\/cmaj.130451","volume":"185","author":"AC Tricco","year":"2013","unstructured":"Tricco AC, Soobiah C, Berliner S, et al. Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis. CMAJ. 2013;185(16):1393\u2013401.","journal-title":"CMAJ"},{"issue":"3","key":"266_CR86","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1192\/bjp.bp.113.127811","volume":"203","author":"C Cooper","year":"2013","unstructured":"Cooper C, Li R, Lyketsos C, Livingston G. Treatment for mild cognitive impairment: systematic review. Br J Psychiatry. 2013;203(3):255\u201364.","journal-title":"Br J Psychiatry"},{"issue":"2","key":"266_CR87","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/1533317509352334","volume":"25","author":"RS Doody","year":"2010","unstructured":"Doody RS, Ferris S, Salloway S, et al. Safety and tolerability of donepezil in mild cognitive impairment: open-label extension study. Am J Alzheimers Dis Other Demen. 2010;25(2):155\u20139.","journal-title":"Am J Alzheimers Dis Other Demen"},{"issue":"6","key":"266_CR88","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S1474-4422(07)70109-6","volume":"6","author":"HH Feldman","year":"2007","unstructured":"Feldman HH, Ferris S, Winblad B, et al. Effect of rivastigmine on delay to diagnosis of Alzheimer\u2019s disease from mild cognitive impairment: the InDDEx study. Lancet Neurol. 2007;6(6):501\u201312.","journal-title":"Lancet Neurol"},{"issue":"3","key":"266_CR89","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/eb-2013-101687","volume":"19","author":"TC Russ","year":"2014","unstructured":"Russ TC. Cholinesterase inhibitors should not be prescribed for mild cognitive impairment. Evid Based Med. 2014;19(3):101.","journal-title":"Evid Based Med"},{"issue":"7","key":"266_CR90","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1001\/archneur.62.7.1164","volume":"62","author":"S Gauthier","year":"2005","unstructured":"Gauthier S, Touchon J. Mild cognitive impairment is not a clinical entity and should not be treated. Arch Neurol. 2005;62(7):1164\u20136 (discussion 1167).","journal-title":"Arch Neurol"},{"issue":"2","key":"266_CR91","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/jama.289.2.210","volume":"289","author":"NH Trinh","year":"2003","unstructured":"Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA. 2003;289(2):210\u20136.","journal-title":"JAMA"},{"issue":"1","key":"266_CR92","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/gps.1402","volume":"21","author":"A Takeda","year":"2006","unstructured":"Takeda A, Loveman E, Clegg A, et al. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer\u2019s disease. Int J Geriatr Psychiatry. 2006;21(1):17\u201328.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"5","key":"266_CR93","doi-asserted-by":"crossref","first-page":"379","DOI":"10.7326\/0003-4819-148-5-200803040-00009","volume":"148","author":"P Raina","year":"2008","unstructured":"Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008;148(5):379\u201397.","journal-title":"Ann Intern Med"},{"issue":"9","key":"266_CR94","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S1474-4422(07)70195-3","volume":"6","author":"H Kavirajan","year":"2007","unstructured":"Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol. 2007;6(9):782\u201392.","journal-title":"Lancet Neurol"},{"key":"266_CR95","doi-asserted-by":"crossref","unstructured":"McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev. 2006;(2):CD003154.","DOI":"10.1002\/14651858.CD003154.pub5"},{"issue":"2","key":"266_CR96","first-page":"211","volume":"3","author":"RA Hansen","year":"2008","unstructured":"Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer\u2019s disease: a systematic review and meta-analysis. Clin Interv Aging. 2008;3(2):211\u201325.","journal-title":"Clin Interv Aging"},{"issue":"3","key":"266_CR97","first-page":"145","volume":"105","author":"JM Ellis","year":"2005","unstructured":"Ellis JM. Cholinesterase inhibitors in the treatment of dementia. J Am Osteopath Assoc. 2005;105(3):145\u201358.","journal-title":"J Am Osteopath Assoc"},{"issue":"10","key":"266_CR98","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S1474-4422(04)00883-X","volume":"3","author":"DB Hogan","year":"2004","unstructured":"Hogan DB, Goldlist B, Naglie G, Patterson C. Comparison studies of cholinesterase inhibitors for Alzheimer\u2019s disease. Lancet Neurol. 2004;3(10):622\u20136.","journal-title":"Lancet Neurol"},{"issue":"6","key":"266_CR99","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2165\/00002018-199819060-00004","volume":"19","author":"A Nordberg","year":"1998","unstructured":"Nordberg A, Svensson AL. Cholinesterase inhibitors in the treatment of Alzheimer\u2019s disease: a comparison of tolerability and pharmacology. Drug Saf. 1998;19(6):465\u201380.","journal-title":"Drug Saf"},{"issue":"9427","key":"266_CR100","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/S0140-6736(04)16499-4","volume":"363","author":"C Courtney","year":"2004","unstructured":"Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer\u2019s disease (AD2000): randomised double-blind trial. Lancet. 2004;363(9427):2105\u201315.","journal-title":"Lancet"},{"issue":"5","key":"266_CR101","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jalz.2009.07.038","volume":"5","author":"LS Schneider","year":"2009","unstructured":"Schneider LS, Sano M. Current Alzheimer\u2019s disease clinical trials: methods and placebo outcomes. Alzheimers Dement. 2009;5(5):388\u201397.","journal-title":"Alzheimers Dement"},{"issue":"11","key":"266_CR102","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.jclinepi.2007.09.012","volume":"61","author":"PE Lee","year":"2008","unstructured":"Lee PE, Fischer HD, Rochon PA, et al. Published randomized controlled trials of drug therapy for dementia often lack complete data on harm. J Clin Epidemiol. 2008;61(11):1152\u201360.","journal-title":"J Clin Epidemiol"},{"key":"266_CR103","doi-asserted-by":"crossref","unstructured":"Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson\u2019s disease dementia and cognitive impairment in Parkinson\u2019s disease. Cochrane Database Syst Rev. 2012;(3):CD006504.","DOI":"10.1002\/14651858.CD006504.pub2"},{"issue":"Suppl 1","key":"266_CR104","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1097\/00002093-200108001-00003","volume":"15","author":"LS Schneider","year":"2001","unstructured":"Schneider LS. Assessing outcomes in Alzheimer disease. Alzheimer Dis Assoc Disord. 2001;15(Suppl 1):S8\u201318.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"9516","key":"266_CR105","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0140-6736(06)68350-5","volume":"367","author":"B Winblad","year":"2006","unstructured":"Winblad B, Kilander L, Eriksson S, et al. Donepezil in patients with severe Alzheimer\u2019s disease: double-blind, parallel-group, placebo-controlled study. Lancet. 2006;367(9516):1057\u201365.","journal-title":"Lancet"},{"issue":"5","key":"266_CR106","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1212\/01.wnl.0000266627.96040.5a","volume":"69","author":"SE Black","year":"2007","unstructured":"Black SE, Doody R, Li H, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology. 2007;69(5):459\u201369.","journal-title":"Neurology"},{"issue":"5","key":"266_CR107","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1159\/000122961","volume":"25","author":"A Homma","year":"2008","unstructured":"Homma A, Imai Y, Tago H, et al. Donepezil treatment of patients with severe Alzheimer\u2019s disease in a Japanese population: results from a 24-week, double-blind, placebo-controlled, randomized trial. Dement Geriatr Cogn Disord. 2008;25(5):399\u2013407.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"1","key":"266_CR108","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1474-4422(08)70261-8","volume":"8","author":"A Burns","year":"2009","unstructured":"Burns A, Bernabei R, Bullock R, et al. Safety and efficacy of galantamine (Reminyl) in severe Alzheimer\u2019s disease (the SERAD study): a randomised, placebo-controlled, double-blind trial. Lancet Neurol. 2009;8(1):39\u201347.","journal-title":"Lancet Neurol"},{"issue":"6","key":"266_CR109","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/gps.1325","volume":"20","author":"H Feldman","year":"2005","unstructured":"Feldman H, Gauthier S, Hecker J, et al. Efficacy and safety of donepezil in patients with more severe Alzheimer\u2019s disease: a subgroup analysis from a randomized, placebo-controlled trial. Int J Geriatr Psychiatry. 2005;20(6):559\u201369.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"7496","key":"266_CR110","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/bmj.38369.459988.8F","volume":"330","author":"C Ballard","year":"2005","unstructured":"Ballard C, Margallo-Lana M, Juszczak E, et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer\u2019s disease: randomised double blind placebo controlled trial. BMJ. 2005;330(7496):874.","journal-title":"BMJ"},{"issue":"3","key":"266_CR111","doi-asserted-by":"crossref","first-page":"843","DOI":"10.3233\/JAD-2010-100078","volume":"21","author":"J Cummings","year":"2010","unstructured":"Cummings J, Jones R, Wilkinson D, et al. Effect of donepezil on cognition in severe Alzheimer\u2019s disease: a pooled data analysis. J Alzheimers Dis. 2010;21(3):843\u201351.","journal-title":"J Alzheimers Dis"},{"issue":"12","key":"266_CR112","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1185\/03007990903396626","volume":"25","author":"L Froelich","year":"2009","unstructured":"Froelich L, Andreasen N, Tsolaki M, et al. Long-term treatment of patients with Alzheimer\u2019s disease in primary and secondary care: results from an international survey. Curr Med Res Opin. 2009;25(12):3059\u201368.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"266_CR113","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1212\/WNL.57.3.489","volume":"57","author":"B Winblad","year":"2001","unstructured":"Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 2001;57(3):489\u201395.","journal-title":"Neurology"},{"issue":"3","key":"266_CR114","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1212\/WNL.57.3.481","volume":"57","author":"RC Mohs","year":"2001","unstructured":"Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology. 2001;57(3):481\u20138.","journal-title":"Neurology"},{"key":"266_CR115","first-page":"391","volume":"10","author":"K Hager","year":"2014","unstructured":"Hager K, Baseman AS, Nye JS, et al. Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer\u2019s disease. Neuropsychiatr Dis Treat. 2014;10:391\u2013401.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"266_CR116","first-page":"CD004744","volume":"5","author":"J Birks","year":"2013","unstructured":"Birks J, McGuinness B, Craig D. Rivastigmine for vascular cognitive impairment. Cochrane Database Syst Rev. 2013;5:CD004744.","journal-title":"Cochrane Database Syst Rev."},{"key":"266_CR117","doi-asserted-by":"crossref","unstructured":"Pagano G, Rengo G, Pasqualetti G, et al. Cholinesterase inhibitors for Parkinson\u2019s disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2014.","DOI":"10.1136\/jnnp-2014-308764"},{"issue":"12","key":"266_CR118","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1111\/j.1532-5415.2001.49266.x","volume":"49","author":"PN Tariot","year":"2001","unstructured":"Tariot PN, Cummings JL, Katz IR, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer\u2019s disease in the nursing home setting. J Am Geriatr Soc. 2001;49(12):1590\u20139.","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"266_CR119","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1517\/14740338.3.5.425","volume":"3","author":"S Thompson","year":"2004","unstructured":"Thompson S, Lanctot KL, Herrmann N. The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer\u2019s disease. Expert Opin Drug Saf. 2004;3(5):425\u201340.","journal-title":"Expert Opin Drug Saf"},{"key":"266_CR120","first-page":"45","volume":"127","author":"F Inglis","year":"2002","unstructured":"Inglis F. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int J Clin Pract Suppl. 2002;127:45\u201363.","journal-title":"Int J Clin Pract Suppl"},{"issue":"7","key":"266_CR121","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2165\/00002512-200421070-00004","volume":"21","author":"DG Wilkinson","year":"2004","unstructured":"Wilkinson DG, Francis PT, Schwam E, Payne-Parrish J. Cholinesterase inhibitors used in the treatment of Alzheimer\u2019s disease: the relationship between pharmacological effects and clinical efficacy. Drugs Aging. 2004;21(7):453\u201378.","journal-title":"Drugs Aging"},{"issue":"11","key":"266_CR122","doi-asserted-by":"crossref","first-page":"853","DOI":"10.2165\/00002512-200118110-00006","volume":"18","author":"S Gauthier","year":"2001","unstructured":"Gauthier S. Cholinergic adverse effects of cholinesterase inhibitors in Alzheimer\u2019s disease: epidemiology and management. Drugs Aging. 2001;18(11):853\u201362.","journal-title":"Drugs Aging"},{"key":"266_CR123","first-page":"55","volume":"1","author":"J Corey-Bloom","year":"1998","unstructured":"Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild-to-moderately severe Alzheimer\u2019s disease. Int J Geriatr Psychopharmacol. 1998;1:55\u201365.","journal-title":"Int J Geriatr Psychopharmacol"},{"issue":"7184","key":"266_CR124","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1136\/bmj.318.7184.633","volume":"318","author":"M Rosler","year":"1999","unstructured":"Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer\u2019s disease: international randomised controlled trial. BMJ. 1999;318(7184):633\u20138.","journal-title":"BMJ"},{"issue":"12","key":"266_CR125","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1212\/WNL.54.12.2269","volume":"54","author":"PN Tariot","year":"2000","unstructured":"Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A, 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology. 2000;54(12):2269\u201376.","journal-title":"Neurology"},{"issue":"10","key":"266_CR126","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/j.1532-5415.1998.tb04537.x","volume":"46","author":"H White","year":"1998","unstructured":"White H, Pieper C, Schmader K. The association of weight change in Alzheimer\u2019s disease with severity of disease and mortality: a longitudinal analysis. J Am Geriatr Soc. 1998;46(10):1223\u20137.","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"266_CR127","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/gerona\/59.1.M68","volume":"59","author":"HH Keller","year":"2004","unstructured":"Keller HH, Ostbye T, Goy R. Nutritional risk predicts quality of life in elderly community-living Canadians. J Gerontol A Biol Sci Med Sci. 2004;59(1):68\u201374.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"2","key":"266_CR128","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/gerona\/58.2.M159","volume":"58","author":"NL Crogan","year":"2003","unstructured":"Crogan NL, Pasvogel A. The influence of protein-calorie malnutrition on quality of life in nursing homes. J Gerontol A Biol Sci Med Sci. 2003;58(2):159\u201364.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"6","key":"266_CR129","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0895-4356(99)00186-9","volume":"53","author":"H Payette","year":"2000","unstructured":"Payette H, Coulombe C, Boutier V, Gray-Donald K. Nutrition risk factors for institutionalization in a free-living functionally dependent elderly population. J Clin Epidemiol. 2000;53(6):579\u201387.","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"266_CR130","first-page":"275","volume":"6","author":"DH Sullivan","year":"2002","unstructured":"Sullivan DH, Morley JE, Johnson LE, et al. The GAIN (Geriatric Anorexia Nutrition) registry: the impact of appetite and weight on mortality in a long-term care population. J Nutr Health Aging. 2002;6(4):275\u201381.","journal-title":"J Nutr Health Aging"},{"issue":"6","key":"266_CR131","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/j.1532-5415.2006.00756.x","volume":"54","author":"JT Stewart","year":"2006","unstructured":"Stewart JT, Gorelik AR. Involuntary weight loss associated with cholinesterase inhibitors in dementia. J Am Geriatr Soc. 2006;54(6):1013\u20134.","journal-title":"J Am Geriatr Soc"},{"issue":"13","key":"266_CR132","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1002\/mds.21669","volume":"22","author":"A Gallini","year":"2007","unstructured":"Gallini A, Sommet A, Salandini AM, Veyssiere P, Montastruc JL, Montastruc JL. Weight-loss associated with anti-dementia drugs in a patient with Parkinson\u2019s disease. Mov Disord. 2007;22(13):1980\u20131.","journal-title":"Mov Disord"},{"issue":"4","key":"266_CR133","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1177\/026988110001400410","volume":"14","author":"NR Dunn","year":"2000","unstructured":"Dunn NR, Pearce GL, Shakir SA. Adverse effects associated with the use of donepezil in general practice in England. J Psychopharmacol. 2000;14(4):406\u20138.","journal-title":"J Psychopharmacol"},{"issue":"11","key":"266_CR134","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1111\/j.1532-5415.2009.02488.x","volume":"57","author":"RK Hernandez","year":"2009","unstructured":"Hernandez RK, Farwell W, Cantor MD, Lawler EV. Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs New England healthcare system. J Am Geriatr Soc. 2009;57(11):1997\u20132003.","journal-title":"J Am Geriatr Soc"},{"issue":"9","key":"266_CR135","doi-asserted-by":"crossref","first-page":"e1000157","DOI":"10.1371\/journal.pmed.1000157","volume":"6","author":"LY Park-Wyllie","year":"2009","unstructured":"Park-Wyllie LY, Mamdani MM, Li P, Gill SS, Laupacis A, Juurlink DN. Cholinesterase inhibitors and hospitalization for bradycardia: a population-based study. PLoS Med. 2009;6(9):e1000157.","journal-title":"PLoS Med"},{"issue":"9","key":"266_CR136","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1001\/archinternmed.2009.43","volume":"169","author":"SS Gill","year":"2009","unstructured":"Gill SS, Anderson GM, Fischer HD, et al. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Arch Intern Med. 2009;169(9):867\u201373.","journal-title":"Arch Intern Med"},{"issue":"1","key":"266_CR137","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2165\/11530300-000000000-00000","volume":"24","author":"A Pariente","year":"2010","unstructured":"Pariente A, Sanctussy DJ, Miremont-Salame G, et al. Factors associated with serious adverse reactions to cholinesterase inhibitors: a study of spontaneous reporting. CNS Drugs. 2010;24(1):55\u201363.","journal-title":"CNS Drugs"},{"issue":"Suppl 2","key":"266_CR138","doi-asserted-by":"crossref","first-page":"ii46","DOI":"10.1093\/ageing\/afl086","volume":"35","author":"M Brignole","year":"2006","unstructured":"Brignole M. Distinguishing syncopal from non-syncopal causes of fall in older people. Age Ageing. 2006;35(Suppl 2):ii46\u201350.","journal-title":"Age Ageing"},{"issue":"1","key":"266_CR139","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/ageing\/22.1.53","volume":"22","author":"S McIntosh","year":"1993","unstructured":"McIntosh S, Da Costa D, Kenny RA. Outcome of an integrated approach to the investigation of dizziness, falls and syncope in elderly patients referred to a \u2018syncope\u2019 clinic. Age Ageing. 1993;22(1):53\u20138.","journal-title":"Age Ageing"},{"issue":"864","key":"266_CR140","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/pgmj.73.864.635","volume":"73","author":"FE Shaw","year":"1997","unstructured":"Shaw FE, Kenny RA. The overlap between syncope and falls in the elderly. Postgrad Med J. 1997;73(864):635\u20139.","journal-title":"Postgrad Med J"},{"issue":"4","key":"266_CR141","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.clinthera.2006.04.011","volume":"28","author":"DD French","year":"2006","unstructured":"French DD, Campbell R, Spehar A, Cunningham F, Bulat T, Luther SL. Drugs and falls in community-dwelling older people: a national veterans study. Clin Ther. 2006;28(4):619\u201330.","journal-title":"Clin Ther"},{"issue":"7","key":"266_CR142","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1002\/jbmr.1616","volume":"27","author":"I Tamimi","year":"2012","unstructured":"Tamimi I, Ojea T, Sanchez-Siles JM, et al. Acetylcholinesterase inhibitors and the risk of hip fracture in Alzheimer\u2019s disease patients: a case-control study. J Bone Miner Res. 2012;27(7):1518\u201327.","journal-title":"J Bone Miner Res"},{"issue":"14","key":"266_CR143","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1212\/WNL.0b013e3181f6128c","volume":"75","author":"KA Chung","year":"2010","unstructured":"Chung KA, Lobb BM, Nutt JG, Horak FB. Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease. Neurology. 2010;75(14):1263\u20139.","journal-title":"Neurology"},{"issue":"4","key":"266_CR144","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/BF03324551","volume":"16","author":"K Kallin","year":"2004","unstructured":"Kallin K, Gustafson Y, Sandman PO, Karlsson S. Drugs and falls in older people in geriatric care settings. Aging Clin Exp Res. 2004;16(4):270\u20136.","journal-title":"Aging Clin Exp Res"},{"issue":"11","key":"266_CR145","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.2165\/00002018-200730110-00005","volume":"30","author":"N Tavassoli","year":"2007","unstructured":"Tavassoli N, Sommet A, Lapeyre-Mestre M, Bagheri H, Montrastruc JL. Drug interactions with cholinesterase inhibitors: an analysis of the French pharmacovigilance database and a comparison of two national drug formularies (Vidal, British National Formulary). Drug Saf. 2007;30(11):1063\u201371.","journal-title":"Drug Saf"},{"issue":"13","key":"266_CR146","doi-asserted-by":"crossref","first-page":"947","DOI":"10.2165\/00023210-200317130-00002","volume":"17","author":"D Bentue-Ferrer","year":"2003","unstructured":"Bentue-Ferrer D, Tribut O, Polard E, Allain H. Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists. CNS Drugs. 2003;17(13):947\u201363.","journal-title":"CNS Drugs"},{"issue":"2","key":"266_CR147","first-page":"57","volume":"7","author":"AL Seritan","year":"2008","unstructured":"Seritan AL. Prevent drug-drug interactions with cholinesterase inhibitors: avoid adverse events when prescribing medications for patients with dementia. Curr Psychiatry. 2008;7(2):57\u201367.","journal-title":"Curr Psychiatry"},{"issue":"12","key":"266_CR148","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1111\/j.1532-5415.2004.52563.x","volume":"52","author":"RM Carnahan","year":"2004","unstructured":"Carnahan RM, Lund BC, Perry PJ, Chrischilles EA. The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice? J Am Geriatr Soc. 2004;52(12):2082\u20137.","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"266_CR149","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1046\/j.1532-5415.2002.50208.x","volume":"50","author":"CM Roe","year":"2002","unstructured":"Roe CM, Anderson MJ, Spivack B. Use of anticholinergic medications by older adults with dementia. J Am Geriatr Soc. 2002;50(5):836\u201342.","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"266_CR150","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s12012-010-9088-5","volume":"10","author":"B Paulison","year":"2010","unstructured":"Paulison B, Leos CL. Potential cardiotoxic reaction involving rivastigmine and beta-blockers: a case report and review of the literature. Cardiovasc Toxicol. 2010;10(4):306\u201310.","journal-title":"Cardiovasc Toxicol"},{"key":"266_CR151","unstructured":"Agency EM. Ebixa. European Public Assessment Report.2004. www.emea.eu.int\/humandocs\/Humans\/EPAR\/ebixa\/ebixa.htm . Accessed 12 Apr 2015."},{"key":"266_CR152","unstructured":"FDA approves memantine drug for treating AD. Am J Alzheimers Dis Other Demen. 2003;18(6):329\u201330."},{"issue":"8","key":"266_CR153","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1001\/archneurol.2011.69","volume":"68","author":"LS Schneider","year":"2011","unstructured":"Schneider LS, Dagerman KS, Higgins JP, McShane R. Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol. 2011;68(8):991\u20138.","journal-title":"Arch Neurol"},{"issue":"6","key":"266_CR154","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/00004850-200211000-00005","volume":"17","author":"G Wilcock","year":"2002","unstructured":"Wilcock G, Mobius HJ, Stoffler A, Group MMM. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol. 2002;17(6):297\u2013305.","journal-title":"Int Clin Psychopharmacol"},{"issue":"7","key":"266_CR155","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1161\/01.STR.0000020094.08790.49","volume":"33","author":"JM Orgogozo","year":"2002","unstructured":"Orgogozo JM, Rigaud AS, Stoffler A, Mobius HJ, Forette F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke. 2002;33(7):1834\u20139.","journal-title":"Stroke"},{"issue":"10","key":"266_CR156","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S1474-4422(10)70194-0","volume":"9","author":"M Emre","year":"2010","unstructured":"Emre M, Tsolaki M, Bonuccelli U, et al. Memantine for patients with Parkinson\u2019s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(10):969\u201377.","journal-title":"Lancet Neurol"},{"issue":"8","key":"266_CR157","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/mds.22495","volume":"24","author":"I Leroi","year":"2009","unstructured":"Leroi I, Overshott R, Byrne EJ, Daniel E, Burns A. Randomized controlled trial of memantine in dementia associated with Parkinson\u2019s disease. Mov Disord. 2009;24(8):1217\u201321.","journal-title":"Mov Disord"},{"issue":"7","key":"266_CR158","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S1474-4422(09)70146-2","volume":"8","author":"D Aarsland","year":"2009","unstructured":"Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson\u2019s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009;8(7):613\u20138.","journal-title":"Lancet Neurol"},{"issue":"6","key":"266_CR159","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/gps.2384","volume":"25","author":"RW Jones","year":"2010","unstructured":"Jones RW. A review comparing the safety and tolerability of memantine with the acetylcholinesterase inhibitors. Int J Geriatr Psychiatry. 2010;25(6):547\u201353.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"1","key":"266_CR160","first-page":"108","volume":"21","author":"N Mimica","year":"2009","unstructured":"Mimica N, Presecki P. Side effects of approved antidementives. Psychiatr Danub. 2009;21(1):108\u201313.","journal-title":"Psychiatr Danub"},{"key":"266_CR161","volume-title":"Essential psychopharmacology: the prescriber\u2019s guide","author":"SM Stahl","year":"2005","unstructured":"Stahl SM. Essential psychopharmacology: the prescriber\u2019s guide. Cambridge: Cambridge University Press; 2005."},{"key":"266_CR162","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1017\/S0714980800006334","volume":"13","author":"J Lindsay","year":"1994","unstructured":"Lindsay J. Patterns of caring for people with dementia in Canada. The Canadian study of health and aging. Can J Aging. 1994;13:470\u201387.","journal-title":"Can J Aging"},{"key":"266_CR163","doi-asserted-by":"crossref","first-page":"925702","DOI":"10.1155\/2013\/925702","volume":"2013","author":"I Molino","year":"2013","unstructured":"Molino I, Colucci L, Fasanaro AM, Traini E, Amenta F. Efficacy of memantine, donepezil, or their association in moderate-severe Alzheimer\u2019s disease: a review of clinical trials. ScientificWorldJournal. 2013;2013:925702.","journal-title":"ScientificWorldJournal"},{"issue":"9","key":"266_CR164","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1089\/jpm.2009.0059","volume":"12","author":"JW Shega","year":"2009","unstructured":"Shega JW, Ellner L, Lau DT, Maxwell TL. Cholinesterase inhibitor and N-methyl-d-aspartic acid receptor antagonist use in older adults with end-stage dementia: a survey of hospice medical directors. J Palliat Med. 2009;12(9):779\u201383.","journal-title":"J Palliat Med"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-015-0266-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-015-0266-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-015-0266-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T15:50:40Z","timestamp":1717861840000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-015-0266-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,5]]},"references-count":164,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["266"],"URL":"https:\/\/doi.org\/10.1007\/s40266-015-0266-9","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,5]]}}}